SG11201701853YA - Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists - Google Patents
Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonistsInfo
- Publication number
- SG11201701853YA SG11201701853YA SG11201701853YA SG11201701853YA SG11201701853YA SG 11201701853Y A SG11201701853Y A SG 11201701853YA SG 11201701853Y A SG11201701853Y A SG 11201701853YA SG 11201701853Y A SG11201701853Y A SG 11201701853YA SG 11201701853Y A SG11201701853Y A SG 11201701853YA
- Authority
- SG
- Singapore
- Prior art keywords
- receptor antagonists
- nmda receptor
- pyrrolopyrimidine derivatives
- nr2b nmda
- nr2b
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050692P | 2014-09-15 | 2014-09-15 | |
| PCT/US2015/050267 WO2016044323A1 (en) | 2014-09-15 | 2015-09-15 | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701853YA true SG11201701853YA (en) | 2017-04-27 |
Family
ID=54293326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701853YA SG11201701853YA (en) | 2014-09-15 | 2015-09-15 | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9567341B2 (de) |
| EP (1) | EP3194403B1 (de) |
| JP (1) | JP6612331B2 (de) |
| KR (1) | KR102569031B1 (de) |
| CN (1) | CN106715435B (de) |
| AU (1) | AU2015317886A1 (de) |
| CA (1) | CA2957898C (de) |
| DK (1) | DK3194403T3 (de) |
| ES (1) | ES2723436T3 (de) |
| IL (1) | IL251027A0 (de) |
| MX (1) | MX2017002775A (de) |
| RU (1) | RU2017107558A (de) |
| SG (1) | SG11201701853YA (de) |
| WO (1) | WO2016044323A1 (de) |
| ZA (1) | ZA201701069B (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015271719A1 (en) | 2014-06-04 | 2016-12-01 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists |
| EP3194403B1 (de) | 2014-09-15 | 2019-02-06 | Rugen Holdings (Cayman) Limited | Pyrrolopyrimidinderivate als nr2b-nmda-rezeptorantagonisten |
| EP3253761A4 (de) | 2015-02-04 | 2018-06-20 | Rugen Holdings (Cayman) Limited | 3,3-difluor-piperidinderivate als nr2b-nmda-rezeptorantagonisten |
| KR102613179B1 (ko) | 2015-06-01 | 2023-12-14 | 뤼겐 홀딩스 (케이맨) 리미티드 | Nr2b nmda 수용체 길항제로서의 3,3-디플루오로피페리딘 카바메이트 헤테로사이클릭 화합물 |
| US10487055B2 (en) | 2016-06-01 | 2019-11-26 | Rhode Island Board Of Education | Diindole compounds useful in treatment of nervous system disorders |
| WO2018098128A1 (en) | 2016-11-22 | 2018-05-31 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| MX2020005869A (es) * | 2017-12-08 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de imidazopiridina y su uso como medicamento. |
| EP4074317A1 (de) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorderivate als neuartige sos1-inhibitoren |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0843661T3 (da) | 1995-08-11 | 2002-07-22 | Pfizer | (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethansulfonat-trihydrat |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| DK1379520T3 (da) * | 2001-02-23 | 2006-08-21 | Merck & Co Inc | N-substituerede ikke-aryl-heterocykliske NMDA/NR2B-antagonister |
| US7592360B2 (en) | 2003-06-04 | 2009-09-22 | Merck & Co., Inc. | 3-fluoro-piperidines as NMDA/NR2B antagonists |
| CA2527093C (en) | 2003-06-04 | 2009-10-20 | Merck & Co., Inc. | 3-fluoro-piperidines as nmda/nr2b antagonists |
| AU2004266227A1 (en) * | 2003-08-15 | 2005-03-03 | Merck & Co., Inc. | 4-cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| US20070293515A1 (en) | 2004-08-03 | 2007-12-20 | Layton Mark E | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists |
| EP1838673A1 (de) | 2004-12-22 | 2007-10-03 | Merck & Co., Inc. | Herstellungsverfahren für substituierte piperidine |
| CN101163482A (zh) * | 2005-04-19 | 2008-04-16 | 默克公司 | N－烷基－氮杂环烷基nmda/nr2b拮抗剂 |
| SI1913000T1 (sl) * | 2005-07-29 | 2012-02-29 | Pfizer Prod Inc | Derivati pirolo(2,3-d)pirimidina; njihovi intermediati in sinteza |
| WO2007061868A2 (en) | 2005-11-17 | 2007-05-31 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors |
| WO2007099828A1 (ja) | 2006-02-23 | 2007-09-07 | Shionogi & Co., Ltd. | 環式基で置換された含窒素複素環誘導体 |
| AU2007338408B2 (en) | 2006-12-27 | 2012-07-26 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives |
| WO2010015637A1 (en) | 2008-08-06 | 2010-02-11 | Novartis Ag | New antiviral modified nucleosides |
| EP2519241A2 (de) | 2009-12-28 | 2012-11-07 | Afraxis, Inc. | Verfahren zur behandlung von autismus |
| CN102939282B (zh) | 2010-04-16 | 2015-12-02 | Ac免疫有限公司 | 用于治疗与淀粉状蛋白或淀粉状蛋白样蛋白有关的疾病的化合物 |
| WO2011156640A2 (en) | 2010-06-09 | 2011-12-15 | Afraxis, Inc. | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS |
| US20130225575A1 (en) | 2010-06-16 | 2013-08-29 | Afraxis, Inc. | Methods for treating neurological conditions |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| EP2683716A1 (de) | 2011-03-11 | 2014-01-15 | Glaxo Group Limited | Pyrido[3,4-b]pyrazinderivate als syk-hemmer |
| DK2713722T3 (en) | 2011-05-31 | 2017-07-03 | Celgene Int Ii Sarl | Newly known GLP-1 receptor stabilizers and modulators |
| EP2838530B1 (de) | 2012-04-20 | 2017-04-05 | UCB Biopharma SPRL | Verfahren zur behandlung von morbus parkinson |
| US9708335B2 (en) | 2013-01-29 | 2017-07-18 | Apytinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| AU2015256075B2 (en) | 2014-05-06 | 2021-02-25 | Northwestern University | Combinations of NMDAR modulating compounds |
| AU2015271719A1 (en) | 2014-06-04 | 2016-12-01 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists |
| EP3194403B1 (de) | 2014-09-15 | 2019-02-06 | Rugen Holdings (Cayman) Limited | Pyrrolopyrimidinderivate als nr2b-nmda-rezeptorantagonisten |
| WO2016049048A1 (en) | 2014-09-22 | 2016-03-31 | Rugen Holdings (Cayman) Limited | Treatment of anxiety disorders and autism spectrum disorders |
| WO2016100349A2 (en) | 2014-12-16 | 2016-06-23 | Rugen Holdings (Cayman) Limited | Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists |
| EP3253761A4 (de) | 2015-02-04 | 2018-06-20 | Rugen Holdings (Cayman) Limited | 3,3-difluor-piperidinderivate als nr2b-nmda-rezeptorantagonisten |
| KR102613179B1 (ko) | 2015-06-01 | 2023-12-14 | 뤼겐 홀딩스 (케이맨) 리미티드 | Nr2b nmda 수용체 길항제로서의 3,3-디플루오로피페리딘 카바메이트 헤테로사이클릭 화합물 |
| WO2018098128A1 (en) | 2016-11-22 | 2018-05-31 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
-
2015
- 2015-09-15 EP EP15779059.3A patent/EP3194403B1/de active Active
- 2015-09-15 MX MX2017002775A patent/MX2017002775A/es unknown
- 2015-09-15 CA CA2957898A patent/CA2957898C/en active Active
- 2015-09-15 DK DK15779059.3T patent/DK3194403T3/en active
- 2015-09-15 KR KR1020177010056A patent/KR102569031B1/ko active IP Right Grant
- 2015-09-15 US US14/855,010 patent/US9567341B2/en active Active
- 2015-09-15 ES ES15779059T patent/ES2723436T3/es active Active
- 2015-09-15 SG SG11201701853YA patent/SG11201701853YA/en unknown
- 2015-09-15 CN CN201580049617.5A patent/CN106715435B/zh active Active
- 2015-09-15 AU AU2015317886A patent/AU2015317886A1/en not_active Abandoned
- 2015-09-15 RU RU2017107558A patent/RU2017107558A/ru not_active Application Discontinuation
- 2015-09-15 WO PCT/US2015/050267 patent/WO2016044323A1/en active Application Filing
- 2015-09-15 JP JP2017514306A patent/JP6612331B2/ja active Active
-
2017
- 2017-02-09 US US15/428,321 patent/US9968610B2/en active Active
- 2017-02-13 ZA ZA2017/01069A patent/ZA201701069B/en unknown
- 2017-03-08 IL IL251027A patent/IL251027A0/en unknown
-
2018
- 2018-04-24 US US15/961,553 patent/US10420768B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017107558A3 (de) | 2019-03-18 |
| BR112017004868A2 (pt) | 2017-12-12 |
| EP3194403A1 (de) | 2017-07-26 |
| US20180303834A1 (en) | 2018-10-25 |
| RU2017107558A (ru) | 2018-10-18 |
| JP2017526724A (ja) | 2017-09-14 |
| MX2017002775A (es) | 2017-08-10 |
| US20160075713A1 (en) | 2016-03-17 |
| DK3194403T3 (en) | 2019-04-15 |
| KR102569031B1 (ko) | 2023-08-22 |
| KR20170049602A (ko) | 2017-05-10 |
| IL251027A0 (en) | 2017-04-30 |
| US20170209449A1 (en) | 2017-07-27 |
| AU2015317886A1 (en) | 2017-03-09 |
| US9968610B2 (en) | 2018-05-15 |
| ZA201701069B (en) | 2019-07-31 |
| ES2723436T3 (es) | 2019-08-27 |
| WO2016044323A1 (en) | 2016-03-24 |
| CA2957898C (en) | 2023-02-21 |
| CN106715435B (zh) | 2019-10-01 |
| JP6612331B2 (ja) | 2019-11-27 |
| CN106715435A (zh) | 2017-05-24 |
| EP3194403B1 (de) | 2019-02-06 |
| US9567341B2 (en) | 2017-02-14 |
| US10420768B2 (en) | 2019-09-24 |
| CA2957898A1 (en) | 2016-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201514875D0 (en) | Receptor | |
| HK1252163A1 (zh) | 受體 | |
| IL251027A0 (en) | History of pyrrolopyrimidines as nr2b nmda receptor antagonists | |
| EP3137074A4 (de) | Prostaglandinrezeptor-ep2-antagonisten, derivate davon, zusammensetzungen damit und verwendungen davon | |
| HK1243638A1 (zh) | 甲氨蝶呤製劑 | |
| HRP20182016T1 (hr) | Derivati etinila | |
| HRP20181585T1 (hr) | Selektivni nr2b antagonisti | |
| EP3154956A4 (de) | Glucagonantagonisten | |
| EP3136858A4 (de) | Guanosin als durch toll-rezeptoren vermittelter immunpotentiator | |
| EP3350167A4 (de) | Androgen-rezeptor-antagonisten | |
| HK1247916A1 (zh) | 新型5-ht2拮抗劑 | |
| EP3193852A4 (de) | Nmda-rezeptor-antagonisten zur behandlung der gaucher-krankheit | |
| HK1231414A1 (zh) | 胃輕癱用 受體激動劑 | |
| TWM489280U (en) | Vibrator table structure |